NBP · NovaBridge Biosciences ADR
United States · RS rating 8 · As of 2026-11-03
| Price | 1.01 USD |
|---|---|
| 1-day change | -5.6% |
| RS rating (overall / 1M / 3M / 12M) | 8 / 16 / 14 / 9 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 8 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +78.5% |
| Market cap (USD) | $285.7M |